Situation of the Prescription service

Situation of the Prescription service

The situation of the joint testing of the Prescription service is compiled on this page. Tabulating starts from joint tests completed on 29 April 2016.

Abilita Hälsovård / Abilita Oy Ab

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings    

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20102016 / 30.12.2016
Functionality for action on behalf of a minor     20072020 / 14.9.2020

 

Acute / Vitec Acute Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20012016 / 30.11.2016
​Forward compatibility of the functionality to act on behalf of a minor     - / 17.2.2020

AssisDent / Entteri Professional Software Oy

   Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
Functionality for action on behalf of a minor 7.10.2020 1. Ongoing,  23.10.2020
2. Not tested
3. Not tested
 

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20062016 / 27.12.2016
Forward compatibility of the functionality to act on behalf of a minor     - / 14.9.2020

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

DomaCare Medi / Invian Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
Refusal to share prescription information  

1. Ongoing,  20.2.2018
2. Not tested
3. Not tested

 

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20142017 / 14.3.2017

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

DynamicHealth / Tieto Healthcare & Welfare Oy

   Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
Functionality for action on behalf of a minor 28.8.2020 1. Ongoing, 31.8.2020
2. Not tested
3. Not tested
 

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20032016 / 30.12.2016
​Forward compatibility of the functionality to act on behalf of a minor     - / 12.3.2020

1= Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

Effica / Tieto Healthcare & Welfare Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20032016 / 9.12.2016

Epic / Epic Helsinki Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     

Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information

    20022018 / 5.10.2018
Forward compatibility of the functionality to act on behalf of a minor     - / 7.9.2020

eRA / Atostek Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20092016 / 29.12.2016
​Functionality for action on behalf of a minor     20032020 / 16.3.2020 
​Functionality for action on behalf of a minor (testing of system changes)    

20052020 / 10.8.2020

 

ESKO / Esko Systems Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20022016 / 9.12.2016
​Forward compatibility of the functionality to act on behalf of a minor     - / 7.5.2020

GFS / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     - / 25.11.2016
​Forward compatibility of the functionality to act on behalf of a minor     - / 6.2.2020
Functionality for action on behalf of a minor     20082020 / 22.9.2020

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

Hilkka / FastROI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20082016 / 30.12.2016
Refusal to share prescription information     20012018 / 11.1.2018
​Forward compatibility of the functionality to act on behalf of a minor     - / 16.4.2020

Kelain / Kela

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20042016 / 9.12.2016
Refusal to share prescription information     20202017 / 1.6.2017
Functionality for action on behalf of a minor     20012020 / 14.1.2020

 

Lifecare /Tieto Healthcare & Welfare Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20192017 / 11.5.2017
​Forward compatibility of the functionality to act on behalf of a minor     - / 14.2.2020

MAXX /Receptum Oy 

Pharmacy system

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20122017 / 11.1.2017
Cross-border prescription     20012019 / 30.9.2019
Functionality for action on behalf of a minor     20062020 / 8.9.2020

 

Mediatri / Mediconsult Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings  

 

 

Accepted joint testings:

     

Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9

    20072016 / 30.12.2016 
Refusal to share prescription information     20212017 / 5.6.2017
​Forward compatibility of the functionality to act on behalf of a minor     - / 5.5.2020
Functionality for action on behalf of a minor     20042020 / 8.10.2020

 

Mediresepti / Mediconsult Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
Functionality for action on behalf of a minor 22.10.2020 1. Ongoing,  27.10.2020
2. Not tested
3. Not tested
 

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20132016 / 30.12.2016
Refusal to share prescription information     20222017 / 4.12.2017 
​Forward compatibility of the functionality to act on behalf of a minor     - / 8.5.2020

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

Navitas / Elisa Appelsiini Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Refusal to share prescription information     20182017 / 24.2.2017

pd3 / Pharmadata Oy

Pharmacy system

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20172017 / 27.1.2017

Cross-border prescription

    20022020 / 20.2.2020
Functionality for action on behalf of a minor     20102020 / 24.9.2020

Pegasos / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20052016 / 20.12.2016
​Forward compatibility of the functionality to act on behalf of a minor     - / 8.4.2020

Salix / Pharmadata Oy

Pharmacy system

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20162017 / 27.1.2017
Cross-border prescription     20022019 / 10.12.2019
Functionality for action on behalf of a minor     20092020 / 24.9.2020

SoftMedic / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
No ongoing joint testings      

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     - / 22.11.2016
Forward compatibility of the functionality to act on behalf of a minor     - / 10.9.2020

Uranus / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date

Ongoing joint testings: 

     
Functionality for action on behalf of a minor 15.7.2020 1. ​Not started
2. ​​Not tested
3. ​​Not tested
 

Accepted joint testings:

     
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20152017 / 11.1.2017
​Forward compatibility of the functionality to act on behalf of a minor     - / 14.1.2020

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

 

Last updated 02.11.2020